Quantitative Bacterial Micro-Assay for Rapid Diagnosis of Galactosemia: Application in Galactosemia Neonatal Screening
author
Abstract:
In the present study a new economic and rapid bacterial micro-assay for simultaneous detection and quantitative measurement of serum galactose was developed. Analysis of the standard curve showed a linearity range for galactose from 2 mg/dL to 180 mg/dL with a regression equation of Y = 0.013X ? 0.083; R² = 0.962. The advantage of the method is its ability to measure serum galactose quantitatively. The cost per sample is about 20-50 cents, which is much less than HPLC and enzymatic commercial kits. The method can be automated, which is suitable for galactosemia neonatal and mass screening especially in developing countries in which funding is a limiting factor.
similar resources
quantitative bacterial micro-assay for rapid diagnosis of galactosemia: application in galactosemia neonatal screening
in the present study a new economic and rapid bacterial micro-assay for simultaneous detection and quantitative measurement of serum galactose was developed. analysis of the standard curve showed a linearity range for galactose from 2 mg/dl to 180 mg/dl with a regression equation of y = 0.013x ? 0.083; r² = 0.962. the advantage of the method is its ability to measure serum galactose quantitativ...
full textNeonatal Screening: Cost-utility Analysis for Galactosemia
BACKGROUND Galactosemia is a congenital metabolic disorder that can damage the health of a newborn. Screening is an important step to prevent and treat this condition. Due to increasing health care costs and limited financial resources of health systems, the most suitable economic analysis tool should be applied. The aim of this study was to analyze the cost-utility of neonatal screening progra...
full textneonatal screening: cost-utility analysis for galactosemia
background: galactosemia is a congenital metabolic disorder that can damage the health of a newborn. screening is an important step to prevent and treat this condition. due to increasing health care costs and limited financial resources of health systems, the most suitable economic analysis tool should be applied. the aim of this study was to analyze the cost-utility of neonatal screening progr...
full textIssues on universal screening for galactosemia.
Galactosemia is an inborn error of galactose metabolism, caused by an abnormality in the conversion of galactose and uridine diphosphoglucose to glucose-1-phosphate and uridine diphosphogalactose through the action of 3 sequential enzymes: galactokinase (GALK), galactose- 1-phosphate uridyltransferase (GALT), and uridine phosphogalactose 4-epimerase (GALE). The advent of newborn screening broug...
full textGalactosemia diagnosis gets an upgrade.
Classic galactosemia, a defect of the metabolism of galactose, was one of the earliest defects of intermediary metabolism to be recognized in the mid 20th century (1, 2 ). The disease is caused by a defect of galactose-1phosphate uridyltransferase (GALT), an enzyme central to the Leloir pathway in which galactose is converted into glucose. Galactose is primarily derived from the lactose content...
full textNeonatal screening for galactosemia by quantitative analysis of hexose monophosphates using tandem mass spectrometry: a retrospective study.
BACKGROUND Classic galactosemia (OMIM 230400) is an inherited disorder in the metabolism of galactose caused by deficiency of the enzyme galactose 1-phosphate uridyl transferase (EC 2.7.7.12). Galactosemia leads to accumulation of galactose and galactose 1-phosphate (gal-1-P) in blood and tissues and, if untreated, produces neonatal death or severe mental retardation, cirrhosis of the liver, an...
full textMy Resources
Journal title
volume 20 issue 4
pages -
publication date 2009-12-01
By following a journal you will be notified via email when a new issue of this journal is published.
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023